title: [Sunitinib and zoledronic acid induced osteonecrosis of the jaw].
abstract: The tendency for bisphosphonate and non-bisphosphonate (eg.: antiresorptive or anti-angiogenesis drugs) induced osteonecrosis is increasing. Treatment of these patients is a challenge both for dentists and for oral and maxillofacial surgeons. Cooperation with the drug prescribing general medicine colleagues to prevent osteonecrosis is extremely important. Furthermore, prevention should include dental focus elimination, oral hygienic instructions and education, dental follow-up and, in case of manifest necrosis, referral to maxillofacial departments. Authors outline the difficulties of conservative and surgical treatment of a patient with sunitinib and zoledronic acid induced osteonecrosis. The patient became symptomless and the operated area healed entirely six and twelve months postoperatively. A long term success further follow-up is necessary to verify long-term success.
authors.affiliation: Arc-, Állcsont- és Szájsebészeti Tanszék, Pécsi Tudományegyetem, Fogorvos-tudományi Kar Pécs, Dischka Győző u. 5., 7621.
authors.forename: Balázs
authors.initials: B
authors.lastname: Soós
authors.affiliation: Arc-, Állcsont- és Szájsebészeti Tanszék, Pécsi Tudományegyetem, Fogorvos-tudományi Kar Pécs, Dischka Győző u. 5., 7621.
authors.forename: László
authors.initials: L
authors.lastname: Vajta
authors.affiliation: Arc-, Állcsont- és Szájsebészeti Tanszék, Pécsi Tudományegyetem, Fogorvos-tudományi Kar Pécs, Dischka Győző u. 5., 7621.
authors.forename: József
authors.initials: J
authors.lastname: Szalma
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000601:surgery; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D008334:Mandible / Q000187:drug effects* / Q000473:pathology / Q000601:surgery*; D019647:Oral Surgical Procedures; D010020:Osteonecrosis / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery*; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D000077210:Sunitinib; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D007211:Indoles; D011758:Pyrroles; D000077211:Zoledronic Acid; D000077210:Sunitinib
keywords: bisphosphonate; biszfoszfonát; osteonecrosis of the jaw; sunitinib; zoledronic acid; zoledronsav; állcsont-osteonecrosis